Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNNOVATE: Niraparib and Neratinib in Advanced Solid Tumors and Ovarian Cancer
NCT04502602Phase 1Active, not recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Aug 2020
- Primary completion
- Oct 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of niraparib and neratinib in solid tumor (advanced stage) and ovarian cancer (6 arms), sponsored by Virginia Commonwealth University. Primary endpoints: Recommended Phase 2 Dose at 4 months and Progression-Free Survival at 4 months. Started Aug 2020; status: active, not recruiting.
02
Drugs
niraparibneratinib
03
Conditions
solid tumor (advanced stage)ovarian cancer
Beyond the preview
Go deeper on NCT04502602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502602.